China News Service, Guangzhou, August 7th (Cai Minjie and He Yuhang) "Due to the lack of public awareness of HPV diseases and the long-term shortage of HPV vaccines, the vaccination rate of HPV vaccines in my country is extremely low, and the vaccination rate of children aged 9 to 14 years old is extremely low. The rate is even less than 1%." Wu Shengming, president of Guangdong Preventive Medicine Association, said at the Guangdong Provincial Cervical Cancer Prevention and Control Strategy Seminar held on the 6th that it is gratifying that in recent years, the public has paid more attention to cervical cancer prevention and control. With the continuous improvement of the level and the accelerated development of local vaccines, domestic HPV vaccines have been launched one after another.

　　HPV's scientific name is "human papillomavirus", and 99.7% of cervical cancers are caused by HPV infection.

Cervical cancer is recognized worldwide as the main "killer" that threatens women's health, ranking fourth in the global female cancer incidence and female cancer mortality rate in 2020, and it is the only cancer with a clear cause, preventable and controllable.

　　As a primary prevention method for cervical cancer, HPV vaccine has been promoted and used in many countries around the world.

Wu Shengming said that as of April 25, 2022, 111 countries/regions have included HPV vaccination in their national immunization programs.

The HPV vaccine needs to be vaccinated before sex as much as possible. The sooner it is vaccinated, the better the vaccine effect.

HPV vaccination is the most effective and cost-effective way to prevent cervical cancer.

It is recommended that girls between the ages of 9 and 14 who have not engaged in sexual activity should be the primary vaccination target, and priority should be given to ensuring a high vaccination rate for this population.

　　Yu Wenzhou, chief physician of the Chinese Center for Disease Control and Prevention, said that the HPV type with the highest infection rate in the country and the world is 16/18 type. Among the cancers caused by HPV infection, 70.8% of cervical cancers are caused by HPV16/18.

The World Health Organization position paper states: From a public health perspective, bivalent, quadrivalent and ninevalent vaccines are comparable in immunogenicity and efficacy in preventing cervical cancer mainly caused by HPV types 16 and 18.

　　According to the epidemiological study of cervical cancer in Chinese women, there are two peak periods of high-risk HPV infection. The first peak period is between 15 and 24 years old, and the second peak period is between 40 and 44 years old. Persistent infection of high-risk HPV is the cause of cervical cancer. main cause of cancer.

　　"What we worry about most is that we don't get vaccinated, and we never do screening. In clinical practice, I have seen many HPV-infected patients in their twenties and thirties. Later, they were actually found to be precancerous. The lesions are even cervical cancer, and the youngest cervical cancer patient I have treated is only 18 years old.” said Qian Deying, director of the Obstetrics and Gynecology Department of Guangdong Provincial People’s Hospital, “These patients in their twenties, if they were vaccinated 10 years ago Without a vaccine, there really will be no today, so I call on everyone to act quickly."

　　Qian Deying also pointed out that if you are vaccinated before the age of 15, you only need two shots, and if you have been vaccinated against HPV before the age of 15, you can have cervical cancer screening every 5 years after the age of 25. If you are not vaccinated, you need to be screened every 2 to 3 years.

　　"When a woman gets an HPV-positive list, the first thing to do is to do a cell scraping test. If the cell scraping test shows that there is also a problem, the second step is colposcopy to confirm the diagnosis." Qian Deying said.

　　Recently, my country's latest bivalent HPV vaccine was launched.

According to Yang Hongwei, director of Watson Biomedical Marketing Department, the vaccine is suitable for women aged 9 to 30 years old. Clinical trials show that women aged 9 to 17 years old were immunized for 42 months, and the positive rates of 16/18 neutralizing antibodies were both It remains above 97%, which shows that HPV vaccination can provide long-term protection for women.

　　Li Xiaomao, a professor of obstetrics and gynecology at the Third Affiliated Hospital of Sun Yat-Sen University, pointed out that the launch of this new HPV vaccine will effectively alleviate the shortage of HPV vaccines, which will add a new option for women to prevent cervical cancer.

(Finish)